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manifestations in children with neuronopathic mucopolysaccharidoses is challenging. Owing to the rarity of
these disorders, multinational studies are often needed to recruit enough patients to provide meaningful data
and statistical power. This can make the consistent collection of reliable data across study sites difficult. To ad-
dress these challenges, an InternationalMPS Consensus Conference for Cognitive Endpointswas convened to dis-
cuss approaches for evaluating cognitive and adaptive function in patients withmucopolysaccharidoses. The goal
was to develop a consensus on best practice for the design and conduct of clinical studies investigating novel
therapies for these conditions, with particular focus on the most appropriate outcome measures for cognitive
function and adaptive behavior. The outcomes from the consensus panel discussion are reported here.
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Mucopolysaccharidoses are inborn errors of metabolism character-
ized by the progressive accumulation of glycosaminoglycans in tissues
throughout the body [1]. There are currently eleven known
mucopolysaccharidoses, each caused by a different lysosomal enzyme
deficiency.
Mucopolysaccharidoses vary in their prevalence and presentation,
although most include extensive somatic involvement affecting the
heart, lungs, airway, bones, joints, vision, hearing, and gastrointestinal
system [1]. In the most severe forms of mucopolysaccharidosis (MPS)
types I, II and III, this is accompanied by central nervous system (CNS)
dysfunction or decline, becoming evident in the second or third year of
life and ultimately resulting in the loss of attained skills. The CNSmanifes-
tations of these conditions are devastating to parents, relentless in their
decline, and result in premature death. CNS manifestations are also ob-
served inMPSVII; an ultra-rare disease that is not discussed in this article.
Treatments for MPS I and II have been available for several years in
the form of hematopoietic cell transplantation (HCT) and enzyme re-
placement therapy (ERT). Although both have been found to have ben-
efits in addressing and preventing progression of many of the somatic
features of these disorders [2–16], only HCT has been found to have
any effect on CNS decline owing to the inability of ERT to cross the
blood–brain barrier [16–20].
Currently, there are several potential disease-modifying products in
pre-clinical and clinical development to address the CNSmanifestations
of MPS I, II and III, with the ultimate aim of preventing or halting the
neurologic decline characteristic of these disorders. The design and con-
duct of clinical studies to evaluate the effects of novel therapies on CNS
manifestations in childrenwith neurodegenerative diseases is challeng-
ing. The most appropriate measures of the effects of novel therapies on
the CNS are changes in cognitive function and adaptive skills (i.e. the
ability to engage in day-to-day activities). Until now there have been a
great variety of approaches taken to evaluate cognition and adaptive be-
havior in patients with mucopolysaccharidoses, which is perhaps un-
derstandable given the plethora of psychometric measurement
instruments available for these purposes. To enable clinicians, investiga-
tors, regulatory bodies and caregivers to fully understand the relative ef-
fectiveness of treatments for mucopolysaccharidoses, it is essential that
standard protocols are applied consistently to ensure reliable measure-
ment of cognitive outcomes and adaptive behavior in clinical trials. The
importance of this was emphasized at a workshop convened by the
Food and Drug Administration on cognitive assessment in inborn errors
of metabolism and in guidelines developed by the National Institutes of
Health (NIH; www.nlm.nih/gov/cde) [21,22]. Owing to the rarity of
mucopolysaccharidoses, multinational studies are often needed to re-
cruit enough patients to providemeaningful data and achieve statistical
power. However, this brings with it diversity of testing languages and
cultures. The availability of the most up-to-date versions of tests also
varies between countries, meaning that older versions of a psychomet-
ric measurement instrumentmay be used by some countries within the
same study.
To address these challenges, an International MPS Consensus Con-
ference for Cognitive Endpoints took place on 2–3 December 2016, or-
ganized by the US and UK MPS Societies and supported by industry.
During this meeting an international panel of experts was convened to
discuss approaches for evaluating cognitive function in patients with
mucopolysaccharidoses. The goal was to achieve consensus on bestPlease cite this article as: J.H. van der Lee, et al., Cognitive endpoints for the
of a consensus procedure, Mol. Genet. Metab. (2017), http://dx.doi.org/10practice for the design and conduct of clinical studies investigating
novel therapies for these conditions, with a focus on themost appropri-
ate outcomemeasures for cognitive function and adaptive behavior. The
outcomes from the consensus panel discussion are reported here.
2. Methods
A modified Delphi technique was used to reach consensus on best
practice for evaluating cognitive and adaptive function in patients with
mucopolysaccharidoses. This methodology, developed by the Rand Cor-
poration/University of California, Los Angeles (UCLA), CA, USA [23], is
based on the original Delphi process [24], which has been widely used
to achieve consensus on a specific issue and is increasingly used for the
developing of clinical guidelines when there is insufficient evidence [20,
25,26]. An overview of the consensus process is shown in Fig. 1.
In consultation with the UK Society for Mucopolysaccharide Dis-
eases and US National MPS Society, an 18-member steering committee
was formed and chaired by Elsa Shapiro, PhD. A comprehensive litera-
ture review was performed by a member of the steering committee –
a psychologist with expertise in another inborn error of metabolism
(DJ) – to consolidate the best available published information on the
methods used to assess cognitive function and adaptive behavior in pa-
tients withMPS diseases, including psychometric properties, usefulness
in various settings, and use and sensitivity to change in MPS diseases.
Full details and findings from the literature review can be found in
Janzen et al. elsewhere in this issue ofMolecular Genetics andMetabolism
[27]. The steering committee discussed and determined the composi-
tion of an expert panel to participate in a Delphi consensus process.
The final composition of the expert panel included four pediatric neuro-
psychologists with expertise in mucopolysaccharidoses, two pediatric
neuropsychologists with expertise in other neurological conditions,
one neurodevelopmental pediatrician with expertise in psychological
assessment in mucopolysaccharidoses, six pediatric physicians with ex-
pertise in mucopolysaccharidoses, a statistician, and a healthcare attor-
ney/MPS caregiver. All participating clinicians and psychologists have
authored peer-reviewed publications on mucopolysaccharidoses, with
the exception of two pediatric neuropsychologists who have published
extensively on neurocognitive testing in their respective fields.
The expert panel convened for a 1-day face-to-face meeting in Lon-
don, UK. The meeting was facilitated by an independent clinical epide-
miologist with experience of conducting Delphi-style consensus
panels. The focus of the meeting was approaches for evaluating cogni-
tive function and adaptive behavior in patients with MPS I, II or III.
Methods for assessing behavior were not included in the discussion.
Before themeeting the panelmemberswere providedwith informa-
tion about 14 measurement instruments previously used to evaluate
cognitive outcomes in patients with mucopolysaccharidoses; these
tools are discussed in detail in Janzen et al. elsewhere in this issue ofMo-
lecular Genetics and Metabolism [27]. Having reviewed this information,
panel members with asked to answer an e-mail survey about:
• Whether they would want to consider these instruments during the
consensus meeting, and
• Their assessment of the importance of 14 measurement characteris-
tics on an 11-point scale (0, not important; 10, very important). Mea-
surement characteristics included the psychometric properties of the
instruments (e.g. reliability, sensitivity, validity), feasibility, and cross-
cultural relevance.rapy development for neuronopathic mucopolysaccharidoses: Results
.1016/j.ymgme.2017.05.004
Fig. 1. Flow chart of the consensus process.
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setting the agenda; deciding the topics for discussion and areas for
recommendation. With regard to choice of which measurement in-
strument to use in each disease and age group, panel members
were first asked to eliminate those that were not relevant or deemed
not suitable for use, and then to rank those measurement instru-
ments that remained. Subsequently, a draft statement for each
topic was proposed by the moderator or by one of the panel mem-
bers and discussed by all panel members. The formulation of each
statement was adapted during the discussion until there was con-
sensus. When considered necessary, the literature review and survey
results were consulted to provide evidentiary support and to remind
panel members of their own priorities.
For some statements, it was decided during the meeting that addi-
tional information from the literature was needed, and several panelPlease cite this article as: J.H. van der Lee, et al., Cognitive endpoints for the
of a consensus procedure, Mol. Genet. Metab. (2017), http://dx.doi.org/10members agreed to provide that information after themeeting. This in-
formation was incorporated into the statements before they were pre-
sented to the panel members for final approval.
Following the consensusmeeting and supplementary research, a full
draft of all consensus statements was sent by email to the panel mem-
bers for comment. In instances where the position of the panel was
not clear, further surveys were sent to all panel members to further ex-
plore the topic in question and to formulate potential recommenda-
tions. Suggested amendments were discussed and agreed via email
and incorporated into the final statements presented here.
3. Results
In the pre-meeting survey, sixmembers (all experts in psychological
testing) of the 15-person panel provided input into which of the 14rapy development for neuronopathic mucopolysaccharidoses: Results
.1016/j.ymgme.2017.05.004
Table 1
Proportion of respondents stating that a particular measurement instrument should be
considered for discussion.
Category Instrument Proportion of
positive
respondents (n =
6)
Test for children b6
years of age
Bayley Scales of Infant and Toddler
Development, Third Edition (Bayley-III)
[28]
100%
Mullen Scales of Early Learning (MSEL)
[29]
50%
Griffiths Scales of Child Development,
Third Edition (Griffiths-III) [30]
33%
Differential Ability Scales, Second
Edition (DAS-II) [31]
67%
Wechsler Preschool and Primary Scales
of Intelligence, Fourth Edition
(WPPSI-IV) [32]
67%
Stanford Binet Intelligence Scales, Fifth
Edition (SB5) [33]
17%
Kaufman Assessment Battery for
Children, Second Edition (KABC-II) [34]
100%
Leiter International Performance Scale,
Third Edition (Leiter-3) [35]
83%
Observer-reported
outcomes,
adaptive Skills
Vineland Adaptive Behavior Scales,
Third Edition (Vineland-3) [36]
100%
Scales of Independent Behavior,
Revised (SIB-R) [37]
50%
Adaptive Behavior Assessment System,
Third Edition (ABAS-3) [38]
50%
N6 years of age Wechsler Abbreviated Scale of
Intelligence, Second Edition (WASI-II)
[39]
67%
Wechsler Intelligence Scale for
Children, Fifth Edition (WISC-V) [40]
67%
Wechsler Adult Intelligence Scale,
Fourth Edition (WAIS-IV) [41]
67%
Table 2
Assessment of the importance of measurement characteristics (scale, 1–10).
Characteristic Importance score (n = 13)
Mean SD Median Min. Max.
Sensitivity to change 9.08 0.93 9 7 10
Feasibility for the specific disease 9.08 1.26 10 5 10
Applicability to a range of functional levels 8.92 1.56 9 7 10
Development characteristics of the test 8.46 1.94 8 7 10
Cross-cultural validity 8.23 1.74 8 4 10
Error of measurement 8.08 1.83 8 7 10
Availability of modern normative data 7.77 0.95 8 6 10
Concurrent validity 7.77 1.36 8 5 10
Content of face validity 7.54 1.44 8 5 10
Availability and familiarity 7.54 1.04 8 5 10
Construct validity 7.46 1.24 8 4 10
Interpretability – MCIDa 7.23 1.98 8 5 9
Ease of administration 7.15 1.13 8 4 10
Additions by responders (n = 1 for each)
Ability to reflect actual cognitive ability
and not merely behavioral aspects of the
child on that day
8.00 – 8 8 8
Acceptability to the participant 7.00 – 7 7 7
a MCID, minimal clinically important difference.
4 J.H. van der Lee et al. / Molecular Genetics and Metabolism xxx (2017) xxx–xxxmeasurement instruments should be considered during the consensus
meeting. The results are shown in Table 1. The instruments that all re-
spondents indicated they would consider were the Bayley Scales of In-
fant and Toddler Development, Third Edition (Bayley-III); the
Kaufman Assessment Battery for Children, Second Edition (KABC-II);
and the Vineland Adaptive Behavior Scales, Third Edition (Vineland-
3). The Stanford Binet Intelligence Scales, Fifth Edition (SB5) was the
least considered; only one respondent wanted to include this instru-
ment in discussions. Full descriptions of each of the instruments
discussed in this article and an explanation of technical terms can be
found in Janzen et al. elsewhere in this issue ofMolecular Genetics and
Metabolism [27].
Thirteen of the 15 panelmembers submitted their assessment of the
importance of the 14 measurement characteristics of the tools to be
discussed (Table 2). “Sensitivity to change” and “feasibility for the spe-
cific disease” were rated the most important characteristics for mea-
surement tools. “Ease of administration” received the lowest score;
although there was not much variability between the scores given
each characteristic. Median scores ranged between 8 and 10. Two fur-
ther characteristics were added, each by one respondent: “ability to re-
flect actual cognitive ability and not merely behavioral aspects of the
child on that day”, which received a score of 8, and “acceptability to
the participant”, which received a score of 7.
At the conclusion of the consensusmeeting, a series of 12 initial con-
sensus recommendations was presented to the group. Following the
meeting, further background research and discussion and revision of
the draft statements via email led to 93% consensus (14 of 15) on the
first statement and full consensus, indicated by expression of agreement
by all expert panel members, on the remaining 11 statements. All are
described below.Please cite this article as: J.H. van der Lee, et al., Cognitive endpoints for the
of a consensus procedure, Mol. Genet. Metab. (2017), http://dx.doi.org/101. For trials evaluating the effect of treatment in childrenwithMPS
I, II or III aged up to 3 years (age equivalent), the recommended
instrument to measure cognitive outcomes is the Bayley-III.
Rationale
Of the available tools for evaluating cognitive function in this age
group, both the Bayley-III (and earlier versions of thismeasure) and
Mullen Scales of Early Learning (MSEL) have been used extensively
in clinical studies of mucopolysaccharidoses in the past [6–9,14,15,
42–61], and both have been shown to be feasible and sensitive to
change in patients with these conditions [8,12,42–45]. Although
earlier versions of the Griffiths Scales of Child Development have
also been used to study the characteristics, natural history and
treatment outcomes in mucopolysaccharidoses, experience with
the latest iteration is limited. Furthermore, the absence of validated
translated versions of the Griffiths-III and the requirement for in-
tensive training on the test indicate that it is not recommended
for use in clinical trials currently, although this may change in the
future.
The availability of validated translations of each measurement
tool is particularly important given the multinational nature of
most trials for mucopolysaccharidoses. The Bayley-III has been
translated and validated in multiple languages, making it an attrac-
tive option for use in multicenter studies, whereas the MSEL has
been translated in only a few countries. Another distinguishing fac-
tor between the Bayley-III and MSEL is the recency of the underly-
ing normative data (Bayley-III, 2004; MSEL, 1980s) [62].
Generally, performance may be overestimated in tests that have
normative datamore than a decade old due to the Flynn effect of in-
creasing IQ over time [63].
A show of hands from panelmembers indicated that the Bayley-
III was used most often in patients under 3 years in this group, al-
though it is not yet available in all countries. It was acknowledged
that the relatively narrow development age range of the Bayley-III
(1–42 months) compared with other instruments (MSEL, 0–
68 months; Griffiths-III, birth–6 years) may necessitate transition
to an alternative instrument in long-term studies.
With these factors in mind, there was 93% consensus among panel
members that the Bayley-III may be the most suitable instrument
for widespread use in clinical trials evaluating cognitive function
in patients with MPS I, II or III, based on the widespread availability
of validated translations of this instrument and the recency of its
normative data. One panel member did not agree with this recom-
mendation, preferring a statement recommending both the Bayley-rapy development for neuronopathic mucopolysaccharidoses: Results
.1016/j.ymgme.2017.05.004
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and the feasibility of use in the population being studied.
2. For trials evaluating the effect of treatment in childrenwithMPS
I, II or III of all ages, the recommended instrument to measure
adaptive behavior is the Vineland, using the extended interview
format.
Rationale
Measures of adaptive behavior help to put scores of cognitive
function into context. A show of hands by panel members indi-
cated that the majority used the Vineland-2 most often when
evaluating children with MPS I, II or III. The Vineland-3 would
also be appropriate, but has only recently been introduced. The
Scales of Independent Behavior, Revised (SIB-R) was viewed as
out of date and is rarely used by this group. The Adaptive Behav-
ior Assessment System, Third Edition (ABAS-3) is never used by
this group. These comments are consistent with the number of
published studies that have used the Vineland-2 (27 studies),
SIB-R (9 studies) and ABAS-3 or prior versions (0 studies) in pa-
tients with mucopolysaccharidoses [7,9,12,14,43–46,48,50,51,
55,56,64–79].
The recently updated Vineland-3 benefits from modern nor-
mative data (2014–2015); especially compared with the SIB-R
(1990s), which is viewed as out of date. The Vineland-3 is also
well correlated to changes in cognitive function compared with
the SIB-R and ABAS-3 [80], and it can be used to determine
which battery of cognitive tests is suitable based on develop-
mental age [68]. With these factors in mind, the Vineland-3 is
recommended as an instrument for evaluating adaptive behavior
in patients of all ages with mucopolysaccharidoses.
The panel noted, however, that to be fully informative, the ex-
tended interview format (approximately 45 min) of the Vine-
land-3 must be used. Wherever possible when using this
format, the same caregiver should be the informant on every
visit to ensure consistency across time points, and examiners
must receive training on how to administer patient/caregiver in-
terviews most effectively. A disadvantage of the Vineland is the
limited availability of the latest version (3) in non-English lan-
guages. However, strong correlation between the second edition
(Vineland-2) and the Vineland-3 means that the earlier version
of this instrument, which is widely available in non-English lan-
guages, can still be used in clinical studies as an alternative. The
newer version also has an improved parent rating form, which
may provide a useful alternative assessment during follow-up
visits or when trained interviewers are not available.
3. For (multinational) trials evaluating the effect of treatment in
children with MPS I aged 3 years and over (age equivalent), the
recommended instruments to measure cognitive outcome are
the Wechsler tests. We recognize the utility of the Kaufman As-
sessment Battery for Children, Second Edition (KABC-II) and
the Differential Ability Scales, Second Edition (DAS-II) in partic-
ular populations because of their reduced fine motor demand
and less emphasis on speed of performance compared with the
Wechsler tests.
Rationale
Of the instruments available for evaluating cognitive function in
patients with a developmental age of 3 years and over, two were
not recommended for use in patients with MPS I. The Leiter-3 was
originally designed for use in deaf children and, although the non-
verbal nature of the instrumentmay have somebenefits in this pop-
ulation, its lower reliability and validity comparedwith other avail-
able instrumentsmeant that this testwas not deemed the strongest
candidate for use in MPS I clinical studies. Similarly, the SB5 has a
large verbal component that makes it suitable for use in older pa-
tients (e.g. 5–6 years), but not in children as young as 3 years
with MPS I.
The DAS-II has been used successfully to assess the longitudinalPlease cite this article as: J.H. van der Lee, et al., Cognitive endpoints for the
of a consensus procedure, Mol. Genet. Metab. (2017), http://dx.doi.org/10effects of HCT in children with MPS I [12]. It was noted that the in-
strument can take a long time to administer (approximately 20–
40 min) and includes a number of tests that rely on previous learn-
ing, which can be challenging for severely affected patients. The
DAS-II is only available in English, although there is a Spanish-lan-
guage supplement available in the early years version. Naturally,
this will limit its utility in multinational clinical trials; however,
the wide developmental age range suitable for the DAS-II (2.6–
18.0 years) makes it an attractive option for longitudinal study
within English- or Spanish-speaking populations.
The Wechsler Preschool and Primary Scales of Intelligence,
Fourth Edition (WPPSI-IV) is available and validated in most lan-
guages and earlier versions of this measure have been used suc-
cessfully to assess the longitudinal effects of bone marrow
transplantation in children with MPS I [8,15]. Some patients
with low developmental ages may struggle with the fine motor
demand and greater emphasis on speed of performance of the
WPPSI-IV compared with the DAS-II and KABC-II. On the other
hand, the WPPSI-IV can be useful when monitoring children
who have been treated successfully and continue to increase
their cognitive skills. Importantly, minimally clinically important
difference (MCID) values have been calculated for the WPPSI-IV.
A potential limitation is the narrow age range of the WPPSI-IV
(2.6–7.7 years), which would require patients to transition to
another test once the ceiling has been reached. However, it is un-
likely that many patients with MPS I will show an increase of N4
age-equivalent years during a clinical trial; plus, similarities in
design mean that transition from the WPPSI-IV to the Wechsler
Intelligence Scale for Children, Fifth Edition (WISC-V; age,
6.00–16.11 years) is likely to be straightforward.
The panel acknowledged the utility of the KABC-II non-verbal
scale owing to its wide age range for use (3–18 years), good reli-
ability and validity. It also benefits from ease of administration in
children with hearing problems and in older patients with low
levels of cognitive function. However, it was deemed to be less
sensitive to change than the Wechsler tests in patients who are
capable of performing the tasks required in the WPPSI-IV and
WISC-V, and may be most useful in older low-function children
with MPS I. Thus, the consensus among panel members was
that age-appropriate Wechsler tests should be used in patients
with MPS I whenever possible, unless the clinical trial design
benefits from alternative measures.
4. For (multinational) trials evaluating the effect of treatment in
children with MPS II or III aged 3–18 years (age equivalent),
the recommended instruments to measure cognitive outcome
are either the DAS-II or the KABC-II. The use of only the non-ver-
bal domain/index may be appropriate if this is necessary to en-
sure consistent application between trial sites across multiple
countries. Other factors to consider in the selection of the mea-
sure andonwhether touse the entire test or only thenon-verbal
domain are: the need for verbal interaction; the time required to
administer the test; fine motor requirements; availability of
normative data; availability of translations.
Rationale
The SB5 and Leiter-3 were not considered appropriate for use in
children with MPS II or III for the same reasons outlined above for
MPS I.
As has been mentioned above, the WPPSI-IV and WISC-V can be
challenging for patients with low development ages owing to task
demands on fine motor skills and sustained attention span, and
the emphasis placed on speed of performance. With this in mind,
the panel felt that theWechsler tests are not suitable for the assess-
ment of cognitive function in children with MPS II or III, who often
exhibit behavioral abnormalities and have low levels of cognitive
function. If treatment is sufficiently effective to allow the child to in-
crease the rate of skill development, as is observed in HCT in MPS I,rapy development for neuronopathic mucopolysaccharidoses: Results
.1016/j.ymgme.2017.05.004
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Wechsler tests may be preferred.
The DAS-II has a large verbal component, which may pose a
challenge to some patients with MPS II or III; although it is possible
to calculate a cognitive function score based on the non-verbal sub-
tests only. The DAS-II has been widely used in patients with MPS II
and takes 20–40min to complete, depending on the age and devel-
opmental capacity of the child [44,45,48,71,81].
The KABC-II has been found to be sensitive to change in patients
with MPS III [43], and it is available and validated in multiple lan-
guages. Its non-verbal components take approximately 30 min to
complete and can be done in pantomime; enabling the administra-
tor to demonstrate to the patient how each task should be complet-
ed. This is particularly useful in patients with low developmental
ages. For such patients, use of the non-verbal components only
may be acceptable in some clinical trial settings with sufficient jus-
tification, especially inmultinational studies or when patients must
cross borders to take part in such initiatives.
Considering the above, the consensus of the panel is that the DAS-II
or the KABC-II should be used in patients with MPS II or III with a
developmental age of 3 years or older.
5. In a set of trials within the same program, we recommend using
the same test protocol for all trial sites worldwide; including, if
possible, the same test editions or, if not, the most recent.
Rationale
Minimizing inter-rater variability is crucial to providing reli-
able data in multisite clinical trials [82], so it is important that
the same test protocol – including the specific measurement in-
strument, choice of subtests and method of administration – is
applied to consistently high standard across all trial sites in a sin-
gle study, but also across an entire program of clinical trials for a
given treatment or disease. Importantly, the study protocol
should be feasible for use in multiple centers and across multiple
languages and cultures, and the risk of loss of accuracy and reli-
ability of data in multicenter studies should be offset through
the use of precise and simple measurements obtained by experi-
enced, highly trained examiners [68,83].
Wherever possible, the same version of the chosenmeasurement
instrument should be used across all sites. Depending on the test
being used, there can be great differences between versions,
both in terms of the normative data underlying them and in
their reliability and applicability in the specific patient popula-
tion being studied, which can threaten trial data validity. In mul-
tinational studies this may present a challenge owing to the
variable availability of translated and validated versions of
some instruments in non-English-speaking countries.
In cases where the most recent version of a measurement instru-
ment is not available in the local non-English language, it may be
acceptable to make use of an earlier version of the same instru-
ment across all sites when the two editions correlate well.
6. Weacknowledge the usefulness and value of historical data that
elucidate the natural history of MPS I, II and III, including stan-
dardized cognitive and developmental outcome measures
other than those recommended in these consensus statements.
Rationale
Although these recommendations provide guidance on themost
robust andwidely available instruments to use to evaluate cognitive
function in patients withmucopolysaccharidoses in futuremultina-
tional clinical trials, this does not discount the value and use of nat-
ural history data for these disorders that were generated using
other cognitive outcome measures.
For example, the MSEL have been used extensively in the study of
cognitive function in patients with MPS I, II and III [9,12,14,44,45,
48,50,57], and the Leiter-3 has played an important role in enhanc-
ing current understanding of the natural history of cognitive decline
in patients with MPS III [50]. The panel strongly recommends thatPlease cite this article as: J.H. van der Lee, et al., Cognitive endpoints for the
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ther study of the neurodegenerative changes in patients with
mucopolysaccharidoses.
7. We strongly recommend building and sustaining an infrastruc-
ture to share natural history data.
Rationale
As with many rare conditions, natural history data relating to
cognitive function in patients with mucopolysaccharidoses are
scarce. The geographic spread of patients with these conditions
makes it likely that data are available for small cohorts of patients
at individual treatment centers, with a variety of measurement in-
struments being used. These data provide valuable insights into
the natural history of mucopolysaccharidoses, and the cumulative
value of these findings is likely to be greater than the sum of their
parts.
The panel strongly recommends the development of an infrastruc-
ture by which investigators around the globe can easily share and
review each other's natural history data in a collaborative fashion.
This will of course rely on thewillingness of both industrymembers
and investigators to collaborate. Recommendations for the design
and implementation of such an initiative are beyond the scope of
this article, but warrant further in-depth discussion.
8. We acknowledge that inmultinational trials itmay be necessary
and appropriate to use one set of psychometrically sound nor-
mative data; however, this is only recommended for a non-ver-
bal outcome measure. If a specified tool has not been validated
in a country,we recommend the parallel use of a country-specif-
ic instrument to establish concurrent validity.
Rationale
Ideally, all instruments used in a multinational trial will have
been translated and validated for use in each country and language
that is taking part in the study, taking into account cultural varia-
tions. This includes validation of normative data to ensure its appro-
priateness for use in the host country. If a fully translated and
validated measurement instrument is not available for use across
all study sites, the choice of normative data against which to evalu-
ate changes in cognitive function becomes an important factor in
the potential success of the trial.
In the absence of a validated translation of themeasurement instru-
ment, an additional country-specific test should be used in parallel
to the main assessment to establish the concurrent validity of the
two tests in each country. This procedure will help to calibrate the
findings of the primary measurement instrument in each country.
9. We recommend the use of a standard written translation of the
measurement instrument, including the administration instruc-
tions, produced by a professional translator with experience
with standardized tests. Such a professional translation should
always be accompanied by a back-translation. We also recom-
mend cross-cultural adaptation. Lastly, we recommend that a
local psychologist/psychometrician should review the fidelity
of the translation and of the cross-cultural adaptation.
Rationale
Translation of cognitive measurement instruments to non-En-
glish languages and cultures is a precise task that must be carried
out in advance of a trial by a skilled professional translator with
knowledge of psychological tests [84]. The translation should be
provided as a standardized written script for use by all assessors
when administering the test. Back-translations should always be
carried out by a third partywho is a native speaker to ensure the ap-
propriateness of the translation. Where possible, the translation
should also be reviewed by a local psychologist/psychometrician
to evaluate thewording and the cultural suitability of the translated
test.
We do not recommend that the assessor translate the instructions
as the test is administered. Similarly, we do not recommend that
verbal instructions to patients are translated by an interpreter inrapy development for neuronopathic mucopolysaccharidoses: Results
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provided to study participants, therefore introducing unnecessary
variability.
For non-native patients attending a study site in another country, it
is acceptable to provide a translator for the testing session to give
non-test-related instructions and assistance. However, the transla-
tor must have received appropriate training so as not to inadver-
tently interfere with standardized test administration.
10. Assessors must be qualified in administering
neurodevelopmentalmeasurement instruments andhave expe-
rience in their use, preferably with the disease being evaluated.
Assessors need to be trained in person to perform the specific
measurements in the protocol and should be subject to periodic
quality control and auditing of scoring.
Rationale
As has been mentioned already in this article, poor inter-rater
reliability, alongwith poor interview quality and rater bias, can sig-
nificantly impact the validity and statistical power of clinical studies
[82,85]. The skilled administration of neurodevelopmental mea-
surement instruments is therefore essential to the generation of re-
liable and robust data [68].
The behavioral challenges that manifest in some patients with
mucopolysaccharidosesmean that familiaritywith these conditions
is extremely beneficial when administering cognitive assessments
[83]. In particular, assessors should have enough clinical experience
with patients who have the disorder being evaluated at all levels of
development to recognize and judge the severity of each cognitive
symptom rated in the scale, and to determine the level of difficulty
of tasks that a child with that condition is likely to be able to per-
form within the protocol [68]. Furthermore, all assessors must be
trained in the use of the test as per the study protocol, including
what constitutes an appropriate environment for assessment and
how to recognize when a test result is not valid and data cannot
be used.
We acknowledge that there are challenges in maintaining reli-
able and valid cognitive assessment for mucopolysaccharidoses.
There is no current, established, published standard for training, su-
pervision and ongoing maintenance of the quality of cognitive as-
sessment, scoring, and data management in clinical trials.
However, it is imperative that even experienced assessors receive
regular re-training and are subject to quality control and monitor-
ing of test administration.
11. We recommend analyzing and reporting age-equivalent scores
in all trials, and standard scores where possible.
Rationale
When considering endpoints for cognitive function in clinical
trials there are three potential metrics that could be used: age-
equivalent scores (i.e. the test score achieved by a healthy individu-
al of that age), developmental quotient (i.e. ratio of age-equivalent
scores to chronological age), and standard scores derived from
test normative data.
Standard scores have traditionally been used as the primary mea-
sure of cognitive function in psychological tests; however, their
use is problematic in patients with low levels of cognitive function
[68]. The standard scores in most tests have a high floor that
many patients with mucopolysaccharidoses will score below, mak-
ing the scores insensitive to any change. Age-equivalent scores have
been used in patients with mucopolysaccharidoses to examine
treatment effects using both cognitive and adaptive behavior scales
[7–9,86]. They are easily interpretable and, when used in a longitu-
dinal context in neurodegenerative diseases, provide information
about whether a child is developmentally progressing, stagnant or
declining. Standard scores anddevelopmental quotients do not pro-
vide this context, but do provide valuable information about the
discrepancy between the patient's development and that of typical-
ly developing peers [68]. Thus, it is preferable to obtain both age-Please cite this article as: J.H. van der Lee, et al., Cognitive endpoints for the
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when possible.
12. When transitioning from one test to another because of devel-
opmental or chronological age, we recommend administering
the two tests concurrently at least once during the same visit
(on separate days) to compare the test results.
Rationale
There is no single test that provides precise measures of all de-
velopmental domains from infancy to adulthood, making it neces-
sary to use different tests across age boundaries. By overlapping
two psychometric tests it is possible to cross-validate the test find-
ings, to see what the discrepancy is and adjust for that discrepancy
in the trajectory [87]. The choice of initial and subsequent tests, the
age-equivalent when the transition should occur, and the approach
to transition between them, should be defined in the study protocol
and/or statistical analysis plan.
4. Discussion
The promise of novel therapies that address the varied CNSmanifes-
tations of mucopolysaccharidoses is encouraging for both families af-
fected by these devastating conditions and the clinicians who treat
them. However, before these treatments can be made available to pa-
tients, it is essential that reliable and consistent data are obtained so
that we can fully understand and feel confident of the effects they
have on neurocognitive development. This consensus document has
been developed to provide a clear set of considered recommendations
based on all available evidence and decades of experience of designing
and administering neuropsychological studies in patients with
mucopolysaccharidoses and related conditions.
Avoiding missteps in the design and implementation of clinical
studies to evaluate natural history and treatment effects on cogni-
tion and adaptive behavior requires an in-depth knowledge of the
relative strengths and weaknesses of the available measurement
tools and when it is appropriate to use them. Investigators must
also consider which scoring system to use to ensure that improve-
ment is detectable, and also have sufficient practical experience
with the conditions being studied to predict and circumvent poten-
tial methodological challenges associated with the somatic and be-
havioral features of the disease. Until now, the formal guidance
available to study sponsors and clinicians working the field of
mucopolysaccharidoses has been limited and varied [46,68,88,89],
with much of the advice provided by the authors of this article. By
bringing together recognized experts in the field and facilitating con-
sensus development through a structured Delphi-based process, we
believe the recommendations listed here will provide much-needed
clarity to a complex yet important area of study.
It was not possible to address here every issue associated with the
study of neurocognition and adaptive behavior, as some aspects are be-
yond the scope of this consensus development process. For example, it
is desirable to calculate MCID values for each of the cognitive tests
discussed, but this is not currently possible without further research.
Similarly, there needs to be extensive and dedicated discussion of how
to develop andmaintain an infrastructure for the sharing of natural his-
tory data among investigators. Both issueswarrant investigation and ac-
tion as a matter of priority.
This is the first example of such a consensus panel on pediatric cog-
nitive and adaptive measures as endpoints in clinical trials in lysosomal
or other neurodegenerative diseases. As new treatments are developed,
such a disease-specific consensus may be a model for conditions other
than mucopolysaccharidoses. It should be noted that the recommenda-
tions described here reflect current understanding and experience with
the instruments available. New tools and new editions and translations
of current tests will inevitably become available in the future. With this
inmind, it will be important that this guidance is reviewed and updated
regularly (e.g. every 3 years) by a panel of appropriate qualified experts.rapy development for neuronopathic mucopolysaccharidoses: Results
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ThemodifiedDelphi process described herewas successful in gener-
ating 12 expert consensus recommendations relating to best practice for
the design and conduct of clinical studies for novel therapies forMPS I, II
and III. It is hoped that the guidance provided in this article will contrib-
ute to the development of robust clinical programs and study protocols
that will help accelerate the development of novel therapies to address
the neurologic impact of these devastating conditions, and enable clini-
cians, regulatory bodies and patients/caregivers to derive a clear unbi-
ased understanding of the relative benefits of the treatment options
available to them.
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